Oxford Biomedica (LON:OXB) Sets New 12-Month High - Still a Buy?

Key Points

• Oxford Biomedica's share price reached a new 52-week high, trading at GBX 458.50 ($6.12), up from a previous close of GBX 440 ($5.88).
• JPMorgan Chase & Co. downgraded Oxford Biomedica's price target from GBX 490 ($6.54) to GBX 400 ($5.34) and assigned a "neutral" rating.
• Insider Heather Preston purchased 11,389 shares at GBX 324 ($4.33) each, increasing her ownership stake to 21.17% in the company.

Shares of Oxford Biomedica plc (LON:OXB - Get Free Report) reached a new 52-week high on Wednesday . The stock traded as high as GBX 458.50 ($6.09) and last traded at GBX 458.50 ($6.09), with a volume of 156349 shares. The stock had previously closed at GBX 440 ($5.84).

Analyst Upgrades and Downgrades

Separately, JPMorgan Chase & Co. dropped their price objective on Oxford Biomedica from GBX 490 ($6.50) to GBX 400 ($5.31) and set a "neutral" rating on the stock in a report on Tuesday, July 15th.

Oxford Biomedica Stock Up 1.3%

The company has a quick ratio of 1.67, a current ratio of 2.35 and a debt-to-equity ratio of 166.48. The company has a market capitalization of £493.77 million, a P/E ratio of -3.45 and a beta of 1.09. The firm has a 50-day moving average price of GBX 347.95 and a two-hundred day moving average price of GBX 333.98.

Insider Buying and Selling at Oxford Biomedica

In other Oxford Biomedica news, insider Heather Preston acquired 11,389 shares of Oxford Biomedica stock in a transaction dated Tuesday, June 17th. The stock was bought at an average cost of GBX 324 ($4.30) per share, with a total value of £36,900.36 ($48,978.44). Corporate insiders own 21.17% of the company's stock.

Oxford Biomedica Company Profile

Oxford Biomedica LSE: OXB is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.